EP Patent

EP3551617A1 — Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists

Assigned to Colucid Pharmaceuticals Inc · Expires 2019-10-16 · 7y expired

What this patent protects

The present invention provides new pseudo-polymorphs of the hemisuccinate salt of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide which are useful in pharmaceutical compositions, for example, for the treatment and prevention of migraine headache.

USPTO Abstract

The present invention provides new pseudo-polymorphs of the hemisuccinate salt of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide which are useful in pharmaceutical compositions, for example, for the treatment and prevention of migraine headache.

Drugs covered by this patent

Patent Metadata

Patent number
EP3551617A1
Jurisdiction
EP
Classification
Expires
2019-10-16
Drug substance claim
No
Drug product claim
No
Assignee
Colucid Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.